06.07.2016 • NewsDede WillamsBASFPE

BASF Closes Sale of Polyolefin Catalysts to Grace

BASF has closed the planned sale of its global polyolefin catalyst business to W. R. Grace, following all approvals. Included in the transaction are technologies, patents, trademarks and the transfer of the German group’s production plants in Pasadena, Texas, and Tarragona, Spain, along with their 170 employees.

Specifically, the business manufactures Lynx high-activity catalyst technologies used in slurry processes to produce HDPE bimodal film and pipe grades and Lynx PP catalyst technologies used in all major PP processes including slurry, bulk loop, stirred and fluid gas, and stirred bulk.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.